rs5030817
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000551.4(VHL):c.464-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000551.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.464-1G>A | splice_acceptor_variant, intron_variant | Intron 2 of 2 | ENST00000256474.3 | NP_000542.1 | ||
VHL | NM_001354723.2 | c.*18-1G>A | splice_acceptor_variant, intron_variant | Intron 2 of 2 | NP_001341652.1 | |||
VHL | NM_198156.3 | c.341-1G>A | splice_acceptor_variant, intron_variant | Intron 1 of 1 | NP_937799.1 | |||
VHL | NR_176335.1 | n.793-1G>A | splice_acceptor_variant, intron_variant | Intron 3 of 3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:2
- -
The 464-1G>A variant has been reported in an individual with VHL syndrome (Glava c 1996). In addition, two similar variants have been reported; 464-1G>T has been reported in three individuals with VHL across three studies and 464-1G>C has be en reported in two individuals with VHL (Crossey 1994, Clinical Research Group f or VHL in Japan 1995, Kanno 1996Ong 2007). Furthermore, the 464-1G>A variant has been identified and confirmed as a somatic variant in renal cell carcinomas (va n Houwelingen 2005, Brauch 2000, Lemm 1999, Banks 2006, COSMIC). This variant is predicted to cause abnormal splicing because the nucleotide substitution occurs in the highly conserved splice consensus sequence. Therefore, this variant is h ighly likely to be pathogenic. Please note this variant has been reported in the literature as 677-1G>A as authors of older manuscripts have numbered the nucleo tides from the start of transcription rather than the start of translation of VH L. -
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
Disruption of this splice site has been observed in individuals with von Hippel-Lindau syndrome (PMID: 8641976, 8707293, 17024664). For these reasons, this variant has been classified as Pathogenic. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 43603). This variant is also known as variants located at c.677-1 and c.677-2. This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 2 of the VHL gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. -
not provided Pathogenic:1
- -
Von Hippel-Lindau syndrome;C0031511:Pheochromocytoma;C1837915:Chuvash polycythemia;CN074294:Nonpapillary renal cell carcinoma Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.464-1G>A intronic variant results from a G to A substitution one nucleotide upstream from coding exon 3 of the VHL gene. This variant has been observed in at least one individual with a personal and/or family history that is consistent with von Hippel-Lindau syndrome (Ambry internal data, Glavac D et al. Hum Genet, 1996 Sep;98:271-80). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at